Auxogyn Takes Top Honor as 'Most Promising Company' at Personalized Medicine World Conference 2012

Feb 09, 2012, 09:00 ET from Auxogyn, Inc.

MENLO PARK, Calif., Feb. 9, 2012 /PRNewswire/ -- Auxogyn, Inc., a privately-held company advancing women's reproductive health, announced today that the Personalized Medicine World Conference (PMWC) and Prescience International selected the Auxogyn as the 'Most Promising Company' at PMWC2012 annual conference, held January 23-24, 2012.

"We are honored to be recognized by industry leaders and our peers as the most promising company for PMWC2012," said Lissa Goldenstein, president and chief executive officer of Auxogyn.  "We look forward to bringing the promise of personalized medicine to the field of assisted reproduction through Eeva, our proprietary non-invasive system that provides objective information on embryo viability to guide patient treatment paths."

Auxogyn was chosen from a group of 31 companies by a group of industry leaders including Paul Billings, M.D., chief medical officer, LIFE Technologies, Rowan Chapman, Ph.D., partner, Mohr Davidow Ventures, Edgar Engleman, M.D., managing partner, Vivo Ventures and Drew Senyei, M.D., managing director, Life Science Practice, Enterprise Partners, as well as audience polling.

"Auxogyn stood out among the presenting companies for its revolutionary approach to improving patient outcomes during in vitro fertilization (IVF) procedures and reproductive health as a whole," said Tal Behar, co-founder of the Personalized Medicine World Conference. "The ability to provide quantitative information for selection of embryos during IVF procedures holds unique promise for the millions suffering from infertility today. We expect novel products like Eeva to play an increasingly significant role in delivering high-quality, cost-effective healthcare in the years to come, and we extend our sincere congratulations to Auxogyn on this premier award."

To qualify for the Most Promising Company Award, a company must be privately-held and working the areas of therapeutics, diagnostics or platform and information technologies. Selection is based on how a company's innovation is disruptive to current standard-of-care, both in cost and effectiveness; strength of team and ability to execute; barriers to competition and strength of intellectual property and expected financial returns for investors.

About Eeva™

Auxogyn's non-invasive early embryo viability assessment (Eeva) system may improve assisted reproduction outcomes by providing IVF clinicians and patients with objective information on embryo viability.  Eeva's proprietary software automatically analyzes embryo development against scientifically and clinically validated cell-division timing parameters.  With Eeva's quantitative data on each embryo's potential development, IVF clinics may be able to select the best embryo(s) for transfer or optimize the treatment path for their patients undergoing IVF procedures. Auxogyn is completing a multi-center, 150-patient clinical trial to validate the safety and efficacy of Eeva, and plans to use the results of the study for regulatory filings in Europe and the United States in 2012.

About Auxogyn

Auxogyn, Inc. is focused on advancing the field of reproductive health through its uniquely-combined knowledge of early human developmental biology, advanced computer vision technology and best clinical practices. The company's first product, Early Embryo Viability Assessment (Eeva), provides quantitative information regarding embryo development, to assist IVF clinics in potentially selecting the best embryo(s) for transfer and optimizing the treatment path for their patients undergoing IVF procedures.  Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, TPG Biotech and Merck Serono Ventures. For more information regarding Auxogyn please visit

SOURCE Auxogyn, Inc.